Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.

Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Latest News...
Oct 27, 2015
Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified... Read More
Aug 13, 2015
- Development of sustained delivery formulations for rapidly growing ophthalmology market - Underpins... Read More
Jul 20, 2015
Midatech (AIM: MTPH) , the international specialty pharmaceutical company with a diversified portfolio of... Read More



Privacy and cookie policy


  © Copyright 2014 Midatech